Jinxin Fertility Group Limited Announces Major Operational Growth in Shenzhen and the United States for Early 2026

Key Highlights from the Recent Corporate Announcement

• Shenzhen Zhongshan Obstetrics and Gynecology Hospital New Campus Launch: The group has commenced trial operations of its new Shenzhen hospital campus as of February 6, 2026. The new facility is in a central location and features a gross floor area of 40,000 square meters, making it approximately four times larger than the original campus.
• Business Growth in Shenzhen: The expansion provides a robust foundation for future business growth, including the hospital’s move into high-value segments such as VIP services, distinctive specialties, and the development of an international medical department.
• Strong Operational Momentum: The Shenzhen operations saw an 18% increase in oocyte pick up cycles (OPU cycles) during the first two months of 2026 versus the same period in 2025, demonstrating accelerated demand and operational throughput.
• Significant Growth in US Operations: In the United States, clinics under the HRC Fertility brand (managed by Jinxin Fertility Group) reported an approximate 38% increase in OPU cycles for the same period, a direct result of regulatory changes in California’s insurance landscape.
• Impact of California SB729: The implementation of California Senate Bill 729 (SB729) in January 2026, which mandates large-corporate health insurance plans (covering over 100 employees) to provide coverage for infertility diagnosis and treatment, has driven local patient demand. The law also allows small and medium-sized employers to opt-in voluntarily. Coverage includes three complete OPU cycles and unlimited embryo transfer cycles, with anti-discrimination clauses regarding marital status and other conditions.

Potential Price-Sensitive Information for Shareholders

• Rapid Expansion and Increased Capacity: The launch of the new Shenzhen campus and the substantial increase in treatment capacity and services could signal sustained revenue growth and improved profitability, presenting a material change in the company’s future earnings outlook.
• Regulatory Tailwinds in the US Market: The implementation of SB729 is a significant regulatory development, likely to boost patient volumes and revenues in the US segment. This change in the reimbursement environment could have a positive impact on the Group’s US operations, which are already experiencing sharp volume growth.
• Early 2026 Performance Metrics: The reported 18% and 38% YoY growth in OPU cycles in Shenzhen and the US, respectively, are strong operating indicators. Such growth rates, if sustained, may positively influence investor sentiment and share valuations.
• Strategic Focus on High Margin Services: The hospital’s plan to expand into VIP and international medical services could result in higher average revenue per patient and improved margins.
• Ongoing Operational Optimization: The company remains committed to advancing operational and clinical excellence, which is essential for maintaining sustainable, long-term value for shareholders.

Other Noteworthy Details

• The information provided is based on preliminary internal assessments and unaudited figures. Investors should note that these numbers are for illustrative purposes only and are not forward-looking statements or formal profit guidance.
• The company urges shareholders and potential investors to exercise caution and rely only on officially released information when making investment decisions.
• Corporate leadership updates: The Board is led by CEO, Acting CFO, and Executive Director Dong Yang, with a diverse mix of executive, non-executive, and independent non-executive directors.

Conclusion

The combination of a major facility expansion in China, strong volume growth in both China and the US, and a favorable regulatory change in a key US market could prove to be significant catalysts for Jinxin Fertility Group Limited’s future performance and share price. These developments underscore the company’s strategic positioning and growth potential in the global fertility services market.

Disclaimer: The above article is a summary and analysis based on the company’s voluntary announcement dated March 4, 2026. All data and projections are preliminary and unaudited. Investors should exercise caution and consult official company disclosures and financial statements before making investment decisions. The author assumes no liability for actions taken based on this article.

View JXR Historical chart here